Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Trials of immune therapies in new-onset type 1 diabetes (T1D) have shown success, but not all subjects respond, and the duration of response is limited. Our aim was to determine whether two courses of teplizumab, an Fc receptor–nonbinding anti-CD3 monoclonal antibody, reduces the decline in C-peptid...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Herold, Kevan C., Gitelman, Stephen E., Ehlers, Mario R., Gottlieb, Peter A., Greenbaum, Carla J., Hagopian, William, Boyle, Karen D., Keyes-Elstein, Lynette, Aggarwal, Sudeepta, Phippard, Deborah, Sayre, Peter H., McNamara, James, Bluestone, Jeffrey A.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2013
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3806618/
https://ncbi.nlm.nih.gov/pubmed/23835333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db13-0345
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky